Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Fig. 1

Similar effects of sacubitril/valsartan on LV function in wild type and in PKGIa LZ mutant mice. a End systolic diameter (ESD) on Day 14 (start of drug) or Day 56 (final day of drug) in WT and PKG LZ mutant mice treated with vehicle, valsartan, or sacubitril/valsartan. b Fractional shortening (FS%) on Day 14 or Day 56 in WT and PKG LZ mutant mice treated with vehicle, valsartan, or sacubitri/valsartan. *p < 0.01 WT day 56 vs WT day 14; #p = 0.06 LZM day 56 vs LZM day 14; p < 0.01 LZM day 56 vs LZM day 14. c Summary data for absolute and relative change in LV fractional shortening from day 14 to day 56. *p < 0.05. For each treatment n = 8 WT, 10–11, LZM

Back to article page